Search This Blog

Monday, November 16, 2026

CG Oncology reports Phase 3 PIVOT-006 trial met its primary endpoint

  reducing bladder cancer recurrence risk by 68% with cretostimogene versus surveillance.

https://finviz.com/stock?t=CGON&p=d

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.